Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 120 50 versus ORETICYL FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 120 50 versus ORETICYL FORTE.
INDERIDE LA 120/50 vs ORETICYL FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
Thiazide diuretic; inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
Hydrochlorothiazide (HCTZ) 50 mg and deserpidine 0.5 mg orally once daily.
None Documented
None Documented
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Deserpidine: 4-12 hours.
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Renal excretion: ~70% as hydrochlorothiazide unchanged; ~30% as deserpidine metabolites via bile/feces.
Category C
Category C
Beta-Blocker/Diuretic Combination
Diuretic Combination